SK Biopharmaceuticals Co., Ltd. (KRX: 326030)
South Korea
· Delayed Price · Currency is KRW
117,800
+8,400 (7.68%)
Oct 11, 2024, 3:30 PM KST
SK Biopharmaceuticals Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Oct '24 Oct 10, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Market Capitalization | 9,334,939 | 7,862,650 | 5,646,385 | 7,612,048 | 13,234,939 | - | |
| Market Cap Growth | -4.20% | 39.25% | -25.82% | -42.49% | - | - | |
| Enterprise Value | 9,288,014 | 7,807,605 | 5,442,304 | 7,267,516 | 12,840,764 | - | |
| Last Close Price | 119200.00 | 100400.00 | 72100.00 | 97200.00 | 169000.00 | - | |
| PE Ratio | 276.49 | -239.11 | -40.50 | 117.39 | -49.02 | - | |
| PS Ratio | 20.07 | 22.16 | 22.94 | 18.18 | 509.06 | - | |
| PB Ratio | 27.60 | 24.50 | 17.84 | 17.14 | 34.91 | - | |
| P/FCF Ratio | -755.08 | -81.41 | -34.26 | -78.32 | -59.68 | - | |
| P/OCF Ratio | -899.29 | -83.47 | -35.31 | -81.96 | -62.81 | - | |
| EV/Sales Ratio | 19.97 | 22.00 | 22.11 | 17.36 | 493.89 | - | |
| EV/EBITDA Ratio | 296.59 | -351.62 | -46.08 | 68.18 | -56.16 | - | |
| EV/EBIT Ratio | 148.94 | -208.08 | -41.52 | 76.53 | -53.62 | - | |
| EV/FCF Ratio | -1155.53 | -80.84 | -33.02 | -74.78 | -57.91 | - | |
| Debt / Equity Ratio | 0.56 | 0.55 | 0.49 | 0.04 | 0.05 | -8.37 | |
| Debt / EBITDA Ratio | 3.58 | - | - | 0.15 | - | - | |
| Debt / FCF Ratio | -25.66 | -1.84 | -0.95 | -0.16 | -0.08 | -1.15 | |
| Asset Turnover | 0.64 | 0.51 | 0.38 | 0.73 | 0.08 | 1.06 | |
| Inventory Turnover | 0.35 | 0.35 | 0.53 | 0.60 | 0.13 | 0.15 | |
| Quick Ratio | 1.18 | 1.47 | 2.28 | 2.64 | 5.67 | 0.58 | |
| Current Ratio | 1.64 | 2.02 | 2.99 | 3.18 | 6.16 | 0.68 | |
| Return on Equity (ROE) | 7.41% | -11.10% | -36.66% | 15.75% | -135.18% | -313.65% | |
| Return on Assets (ROA) | 3.47% | -3.38% | -12.53% | 10.38% | -46.83% | -42.23% | |
| Return on Capital (ROIC) | 4.93% | -4.83% | -17.57% | 13.84% | -60.65% | -64.06% | |
| Earnings Yield | 0.36% | -0.42% | -2.47% | 0.85% | -1.87% | - | |
| FCF Yield | -0.09% | -1.23% | -2.92% | -1.28% | -1.68% | - | |
| Buyback Yield / Dilution | - | - | -9.12% | -10.41% | -4.42% | |
| Total Shareholder Return | - | - | -9.12% | -10.41% | -4.42% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.